The KDA is delighted to welcome Delery Rice as KDA's first Executive Director who joined the KDA team on October 5, 2026. With more than 20 years of nonprofit leadership experience, Delery brings a wealth of expertise in fundraising, strategic development, disability advocacy, and building partnerships that make a difference in people’s lives.
Experimental drug AJ201 (also called rosolutamide) is moving into a Phase 3 clinical trial for Kennedy's Disease
The Kennedy’s Disease Association (KDA) is launching KD Voices, a new initiative that will give people affected by Kennedy’s Disease an opportunity to share their experiences, perspectives, and priorities directly with pharmaceutical and biotechnology companies developing potential treatments.
